Guanosine reduces apoptosis and inflammation associated with restoration of function in rats with acute spinal cord injury
- First Online:
- Cite this article as:
- Jiang, S., Bendjelloul, F., Ballerini, P. et al. Purinergic Signalling (2007) 3: 411. doi:10.1007/s11302-007-9079-6
- 414 Views
Spinal cord injury results in progressive waves of secondary injuries, cascades of noxious pathological mechanisms that substantially exacerbate the primary injury and the resultant permanent functional deficits. Secondary injuries are associated with inflammation, excessive cytokine release, and cell apoptosis. The purine nucleoside guanosine has significant trophic effects and is neuroprotective, antiapoptotic in vitro, and stimulates nerve regeneration. Therefore, we determined whether systemic administration of guanosine could protect rats from some of the secondary effects of spinal cord injury, thereby reducing neurological deficits. Systemic administration of guanosine (8 mg/kg per day, i.p.) for 14 consecutive days, starting 4 h after moderate spinal cord injury in rats, significantly improved not only motor and sensory functions, but also recovery of bladder function. These improvements were associated with reduction in the inflammatory response to injury, reduction of apoptotic cell death, increased sparing of axons, and preservation of myelin. Our data indicate that the therapeutic action of guanosine probably results from reducing inflammation resulting in the protection of axons, oligodendrocytes, and neurons and from inhibiting apoptotic cell death. These data raise the intriguing possibility that guanosine may also be able to reduce secondary pathological events and thus improve functional outcome after traumatic spinal cord injury in humans.
KeywordsApoptosisCell deathGliaGuanosineImmunohistochemistryInflammationLocomotor and sensory functionMyelinSpinal cord injury
Basso-Beattie-Bresnahan locomotor rating scale
basic fibroblast growth factor
cyclic adenosine monophosphate
cerebral spinal fluid
foot orienting response
glial fibrillary acidic protein
hind limb placing response
inclined plane test
lower urinary tract
mitogen-activated protein kinase
myelin basic protein
nerve growth factor
open field walking test
protein kinase B
spinal cord injury
standard error of the mean
terminal deoxynucleotidyl transferase
tumor necrosis factor-alpha
terminal deoxynucleotide transferase dUTP nick end labeling
Spinal cord injury (SCI) occurs in an instant, but its devastating effects last a lifetime at huge personal and economic cost . The spinal cord conveys both afferent sensory and efferent motor information, so disruption of spinal cord function results not only in motor paralysis but also sensory and autonomic impairment distal to the injury [2, 3]. Sensory dysfunction contributes to the generation of pressure sores that, like bladder impairment, are a major source of morbidity and even mortality in those with spinal cord injury .
Restoration of function in longstanding spinal cord injuries is poor, although some limited functional restoration has been reported . Therefore, there is much interest in reducing the extent of the initial damage from traumatic spinal cord injury in the acute phase. Trauma often results in primary damage resulting from mechanical disruption of the nerve axons in the spinal cord that is not amenable to neuroprotective therapy. However, secondary pathological changes involving cascades of biochemical, molecular, and cellular changes can produce even more extensive damage, and these changes are potentially susceptible to therapeutic intervention with neuroprotective agents [3, 6]. Thus, pathological changes occur from the moment of injury and continue for years afterwards and have been divided into three phases: an acute phase, a phase of secondary tissue loss, and a chronic phase [3, 6].
In the acute phase, which starts at the moment of injury and extends over the first few days, numerous pathological processes begin. Mechanical injury induces an immediate change in neuronal tracts at the moment of impact, blood flow is reduced, creating substantial ischemic necrosis [7, 8] and a cascade of pathophysiological processes rapidly follows mechanical trauma to the spinal cord, resulting in secondary neuronal damage that can significantly exacerbate the original injury . Traumatic injury to the spinal cord also leads to a strong inflammatory response, with the recruitment of peripherally derived inflammatory cells, including macrophages . Damage to the spinal cord also results in extensive cell proliferation in and around the epicenter, many of which are microglia and macrophages. This acute inflammatory response at the site of the initial lesion is at least partly responsible for secondary spinal cord pathology [11–13]. The inflammatory cells (particularly macrophages/microglia) can mediate tissue damage by producing a variety of cytotoxic factors including interleukins , tumor necrosis factor-alpha (TNF-alpha) , and reactive nitrogen species [13, 16–18]. Neuronal and oligodendroglial cell loss is apparent in the lesion epicenter, and rostral and caudal to it within 4 h of injury . From days to years after the initial trauma, apoptotic cell death continues, and scarring and demyelination accompany Wallerian degeneration. All these processes contribute to motor and sensory functional deficits [20, 21].
Many pharmacological agents have been reported to reduce secondary injury and to be neuroprotective in a variety of animal models; these include anti-inflammatory [22–24] and antiapoptotic agents [24, 25] and agents that elevate cyclic adenosine monophosphate (cAMP) [26, 27]. None has yet proved effective in ameliorating the effects of acute spinal cord injury in clinical trials in humans.
There is increasing evidence that the non-adenine-based purine guanosine acts as an intercellular signaling molecule. It is released from cells and has several diverse effects on cells in vivo and in vitro, particularly trophic effects modulating cellular growth, differentiation, and survival [28, 29]. Guanosine has a number of effects on various cell types that make it a good candidate to test as a neuroprotective agent in acute spinal cord injury since it might potentially interact with several steps of the biochemical and cellular cascade. It is neuroprotective [28–32] and stimulates nerve regeneration [5, 33]. It also protects several cell types against apoptosis induced by a variety of agents such as staurosporine  and beta-amyloid  and has been reported to increase intracellular cAMP [36, 37]. Therefore, in the present study, we assessed whether guanosine might ameliorate tissue damage and enhance functional outcome after acute spinal cord injury.
Materials and methods
Adult female Wistar rats (280–300 g body weight, Charles River) were maintained in a temperature-controlled vivarium on a 12:12-h light-dark cycle with food and tap water freely available. Rats were handled daily for 2 weeks before surgery.
Spinal cord injury induction and experimental design
Spinal cords were surgically exposed and compressed with modified coverslip forceps to produce a moderate traumatic spinal cord injury [5, 38]. Before surgery, rats were given buprenorphine (0.03 mg/kg body weight, subcutaneously) for pain relief. They were then anesthetized with isoflurane (3–5%): O2 (1 l/min) and a laminectomy was performed at T11/T12 to expose the spinal cord that was then crushed with modified coverslip forceps [5, 38–40]. The forceps were closed slowly (over 2 s) compressing a 5-mm length of the spinal cord to a thickness of 1.4 mm for 15 s. The wound was closed by suturing the muscles and fat pad, and by clipping the skin with stainless steel clips. Postoperatively, the rats were kept quiet and warm.
To evaluate the effect of guanosine on acute phase SCI pathophysiology, we studied two groups of rats (n = 24) with SCI. After surgery and prior to treatment, behavioral tests were done for each rat. Two of the total 24 animals were excluded from the study because of incorrect injury (BBB score at the surgery day before treatment below 4 or above 7; in our experience, about 91% of rats with this degree of crush were within the range of 5 to 6 on the BBB scale at first day after injury ). The 22 rats were then randomly divided into two groups. Starting 4 h after surgery, rats received either daily intraperitoneal (i.p.) injections of 8 mg/kg guanosine or the same volume of saline containing 0.001 N NaOH  for 2 weeks. On day 7 after injury one animal in the saline group was euthanized because of a severe bladder infection.
Motor and sensory functional recovery assessment
All rats were handled daily for 2 weeks preoperatively to acclimatize them to the handling and behavioral testing. After spinal cord compression, the locomotor behavior segmental reflexes and spinothalamic senses of the rats were assessed immediately prior to treatment (day 0) and on days 1, 3, 5, 7, 14, 21, and 28 after the injury. Five tests were used: an open field walking task [5, 41, 42], hind limb placing response [38, 40], foot orienting response [38, 40, 43], an inclined plane test [38, 44, 45], and a hot plate test . Behavioral analyses were performed by individuals who were blinded with respect to treatment groups.
An open field walking testing (OFWT) was used to assess the locomotor functional recovery of the hind limb. It was conducted in a child’s circular plastic swimming pool (1.3 m in diameter [5, 38]). Cagemates (two animals) were placed in the center of the open field. They were observed for 5-min periods and scored for general locomotor ability using the standard BBB scale. The rats were rated on a scale of 0 to 21, 0 being no function and 21 being normal. If the animal stopped moving for a minute, it was placed again in the center of the open field; otherwise it was left undisturbed for the duration of the 5-min test period.
Reflexes in the hind limbs were assessed with hind limb placing response (HLPR) and foot orienting response (FOR). They were each scored on a scale of 0 to 2, 0 indicating no function and 2 indicating full function [38, 40, 43]. Half-scores were assigned if the behavioral response appeared intermediate. Hind limbs were scored separately for each measure. To assess HLPR, we grasped the hind foot between the thumb and forefinger, pulled backwards, and then released the foot. The placement of the foot on the table surface was then scored [38, 40]. The FOR followed Gruner’s  protocol modified from the previous descriptions of this reflex . When a rat is raised and lowered by the tail, it shows a characteristic behavior of the hind legs. A normal rat spreads the toes of its hind leg wide apart and generally holds them apart for several seconds. After spinal cord injury, this response is sometimes lost completely, or reduced in magnitude.
The inclined plane test (IPT) measured the ability of the rats to maintain their position for 5 s on an inclined plane, covered by a rubber mat containing horizontal ridges (1 mm deep, spaced 3 mm apart, self-made) . The rats were observed as the angle of the surface was increased from 5 to 90° at 5° intervals. The angle at which the rat could no longer stay in position was the outcome measure.
Hind limb sensory function was tested by ability to perceive a standard application of a controlled stimulus to the trunk below the level of the lesion using a standard testing apparatus hot plate (IITC Life Science Inc., Woodland Hills, CA, USA) . The time taken for the rat to withdraw its hind paws from contact with the hot plate was noted. A cutoff time was about 20 s after which the animals were removed to prevent thermal injury .
Recovery of lower urinary tract function
Normal lower urinary tract (LUT) function involves both spinal and supraspinal circuitry that controls urine storage and release . Incomplete SCI results in an initial loss and later partial or complete recovery of LUT function depending on the severity of injury [48, 49].
After SCI the rats were not capable initially of spontaneous micturition, and their bladders were manually expressed twice daily. The volume of expressed urine was measured each time, and the data were used to estimate the initiation of LUT function after SCI.
Tissue processing and immunohistochemical staining
Twenty-eight days after SCI, animals were killed for histological and immunohistochemical analysis. Rats were deeply anesthetized with sodium pentobarbital (50–60 mg/kg b/w, i.p.) and perfused transcardially; first with 100 ml 0.05 M phosphate-buffed saline (PBS) containing 0.1% heparin, followed by 300–500 ml of 4% paraformaldehyde (PFA). The T9 to L1 segments of the spinal cords were removed and incubated in the same fixative solution overnight at 4°C and then cryoprotected in PBS solution containing 30% sucrose. A segment of each cord, extending from 5 mm rostral to 5 mm caudal to the lesion site was embedded in medium (Tissue-Tek® O.C.T. compound, Sakura Finetek USA, Inc., Torrrance, CA, USA). Serial sections were cut at 20-μm intervals on a cryostat and mounted onto slides (ColorFrost/Plus; Fisher, Pittsburgh, PA, USA) for histochemical staining. Some cords were transverse-sectioned for immunohistochemical analysis using the antibodies described in the section below. Longitudinal sections were cut for Luxol fast blue staining, a lipophilic dye used commonly to stain myelin .
Details of these immunohistochemical procedures have been described previously [5, 38]. Briefly, the cryostat sections were thawed, air-dried, and then incubated in hydrogen peroxide to reduce endogenous peroxidase activity, before being rinsed in PBS. The sections were then incubated in 1% sodium borohydride for 15 min. After thorough washing with PBS, the sections were treated with PBS/5% normal goat serum with 0.3% Triton X-100 at room temperature for 30 min. Overnight incubation with primary antibody was performed in humidified boxes at 4°C. Macrophages and reactive microglia were detected with a mouse monoclonal antibody against ED-1 (MCA 341R, 1:500; Serotec, Hornby, ON, Canada) and reactive astrocytes (astrogliosis) were determined with rabbit anti-glial fibrillary acidic protein (GFAP) polyclonal antibodies (Zymed® Lab-SA System Kit, dilution was 1:600, Invitrogen Canada Inc., Burlington, ON, Canada). The following day, sections were rinsed with PBS and incubated with either rhodamine-conjugated or fluorescein isothiocyanate (FITC)-conjugated secondary antibodies. Sections were then rinsed, coverslipped, and examined under a confocal microscope.
To determine the spared axons and myelin, double fluorescent immunolabeling was performed, combining mouse monoclonal antibodies against neurofilament (RT-97, 1:10; Developmental Hybridoma Bank) and rabbit anti-myelin basic protein (MBP) polyclonal antibodies (1:50; Chemicon Int., Temecula, CA, USA). For double immunolabeling, sections were developed using a mixture of FITC-conjugated goat anti-rabbit IgG and rhodamine-conjugated goat anti-mouse IgG in 1% normal goat serum and 0.25% Triton X-100; 1:200 (Invitrogen Canada Inc., Burlington, ON, Canada) for 2 h. Sections were then rinsed, coverslipped, and examined under a confocal microscope. An investigator who was blinded to the treatment groups conducted histological analysis.
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling assays and quantification
For detection of apoptotic cells, a terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) stain was performed using the “In situ Cell Death Detection Kit-Fluorescein” (Roche Molecular Biochemicals, Chemicon Int., Temecula, CA, USA), according to the manufacturer’s instructions. After fixation, tissue sections were incubated in TdT-mediated dUTP-biotin nick end labeling (TUNEL) reaction mixture containing TdT buffer with TdT and biotinylated dUTP in TdT buffer, incubated in a humid atmosphere at 37°C for 90 min, and then washed with PBS. The sections were incubated at room temperature (37°C) for 30 min with fluorescence-conjugated antibody. The results were analyzed using confocal fluorescence microscopy. TUNEL-positive cells in the lesion site in the spinal cord were quantified by counting positively stained cells. Sections (5–7 per animal) taken from the penumbra of the lesion and spaced about 100 μm apart were analyzed for each animal (n = 3–5 animals per group). Apoptotic cell death was determined by counting the total number of TUNEL-positive nuclei through entire cross sections. Low power sections were digitized and manually outlined using an image analysis system. Any cavities present in the sections were excluded from analysis. Data are expressed as cells per section .
For cell counting, 5–7 sections from each animal (n = 5 for each group) at the lesion site (every third section, 100 μm apart) were analyzed. OX-42-positive microglia and TUNEL-positive nuclei were counted through the entire cross section. Data are expressed as the number of immunostained cells per section (mean ± SEM).
All data are presented as mean ± SEM. The statistical significance of behavioral scores was analyzed by Kruskal-Wallis nonparametric analysis of variance followed by Mann-Whitney U tests. Histological data were evaluated by Student’s t-tests.
Guanosine improves neurological function
Guanosine accelerated LUT functional recovery following SCI
Guanosine attenuates macrophage and microglia activation, but not astrogliosis
Guanosine attenuates apoptotic cell death in lesion site of spinal cord
Guanosine increases axon and myelin sparing
These data are the first to demonstrate the ability of guanosine to act as a neuroprotective agent in vivo. These findings have potential clinical relevance. Previous studies have shown that after central nervous system injuries, the concentrations of guanosine are elevated around the injury and in CSF, sometimes for prolonged periods [32, 52]. Given the various trophic and antiapoptotic effects of guanosine in vitro [28, 34, 35], it seemed likely that increasing the concentration of guanosine in the central nervous system after injury in vivo might also be neuroprotective. We found that within 7 min of systemic administration, guanosine enters and progressively accumulates in the central nervous system (unpublished data), where it is converted to guanine. It remains to be determined whether guanosine, guanine, or both are the active neuroprotective agent. However, guanosine is more readily deliverable than guanine as a potential neuroprotectant.
The model of incomplete spinal cord injury that we have used is clinically relevant since about 50% of patients with spinal trauma have incomplete injury . After incomplete spinal cord injury, both reflex and voluntary motor functions below the level of the injury are initially lost; partial recovery occurs over time [41, 54, 55]. The recovery of functions mediated by supraspinally controlled reflexes is slow and incomplete since these require the function of long tracts, many of which are irreversibly damaged by the injury [56, 57]. Recovery of locomotion and limb placement depends on ascending and descending spinal cord tracts, including cortico-, rubro-, reticulo-, vestibulo-, and raphespinal tracts . The functional loss after spinal cord injury in rats involves interruption of descending serotonergic , reticulospinal, and other descending spinal tracts that facilitate segmental reflexes [40, 60]. The ascending spinothalamic tracts mediate the perception of pain and temperature below the level of the lesion. Since all of these motor and sensory functions were better in guanosine-treated animals than in control animals, it appears that guanosine preserved the function of multiple long tracts. This was associated with increased axonal survival and myelin preservation.
Normal micturition requires coordinated activation of the bladder smooth muscle (detrusor) and the striated muscle of the external urethral sphincter, controlled by spinal and supraspinal circuitry . Thus after incomplete spinal cord injury, initially bladder function is lost, but later partially recovers, the extent of recovery depending on the degree of preservation of white matter (and hence the long tracts) at the injury site [48, 49]. Our data revealed that in guanosine-treated rats, residual urine volume was not only much less than in controls from the first day after the spinal cord injury, but that by 7 days after spinal cord injury micturition had returned to normal. Because guanosine began to exert a neuroprotective effect on both motor and bladder function soon after it was first administered, its neuroprotective effect on each may involve similar mechanisms.
The inherent complexity of the biological system coupled with the many potential trophic actions of guanosine make it difficult to determine the mechanisms by which guanosine produces its effects. Nevertheless, neuroprotective effects were observed by 24 h after spinal cord injury. As guanosine was administered 4 h post-injury, it must have affected processes that were important between 4 and 24 h post-injury. Within this time frame after traumatic injury of the spinal cord, both inflammatory responses and apoptosis are prominent. Activation and proliferation of microglia/macrophages play an important role in the secondary damage following spinal cord injury. Thus, cells at the center of the injury cascade are potential targets for neuroprotective treatments of acute SCI [21, 61]. As guanosine attenuated the activation and proliferation of microglia/macrophages following SCI, this may at least in part provide an explanation for its neuroprotective effect.
Guanosine has antiapoptotic effects in vitro [34, 35] and this is another potential mechanism through which guanosine might exert beneficial effects after spinal cord injury. Apoptosis after SCI has been described by many investigators [15, 62–67]. In these reports, early apoptosis of neural cells, including neurons, is followed by a delayed wave of predominantly oligodendroglial-programmed cell death in degenerating white matter tracts [63–67]. Studies of apoptosis in white matter after injury raise the possibility that glial apoptosis occurs, at least in part, as a consequence of axonal degeneration [68, 69]. However, the presence of activated microglia in contact with apoptotic oligodendrocytes after SCI indicates that this interaction may also activate cell death programs in the oligodendrocyte . Secondary axonal degeneration may then follow [71, 72]. In the present study, guanosine significantly suppressed apoptosis in the injured spinal cords when it was systemically administered daily for 2 weeks beginning 4 h after injury. It seems reasonable to postulate that decreasing apoptosis may be an important mechanism through which guanosine improves neurological outcome after SCI.
Although the intracellular pathways through which guanosine suppresses apoptotic cell death following spinal cord injury are not known, a number of intracellular pathways which protect cells against apoptosis have been identified. These include the phosphatidylinositol 3-kinase (PI-3-K)/Akt/protein kinase B (PKB) pathway [73, 74] and the mitogen-activated protein (MAP) kinase pathway . Our previous studies in vitro have shown that the antiapoptotic effect of guanosine is mediated by the activation of both PI-3-K/Akt/PKB and MAPK pathways [34, 35].
Guanosine can also increase intracellular cAMP in various cell types [36, 37], and increases in cAMP after spinal cord injury have been shown to increase recovery [26, 27]. However, it appears unlikely that increases in intracellular cAMP are responsible for the effects of guanosine since the principal effect of cAMP in enhancing recovery from spinal cord injury appears to be due to its ability to promote axonal regeneration. In contrast, the neuroprotective effects we observed early after administration of guanosine are unlikely to be explained on the basis of outgrowth of damaged axons. A much longer time frame could be required for this to occur.
A further possible mechanism by which guanosine might exert its neuroprotective effects is by stimulating cells to release and increase synthesis of various trophic factors, such as basic fibroblast growth factor (bFGF), nerve growth factor (NGF), and neurotrophin-3 (NT-3) . Such trophic factors can contribute to tissue preservation after trauma . The ability of guanosine to stimulate production and release of trophic factors may not only have early effects, but also may contribute to the reduced number of apoptotic cells observed 3 weeks after the injury.
This study is important not only because it is the first to demonstrate the neuroprotective effect of systemically administered guanosine in acute spinal cord injury, but also because it indicates some of the potential mechanisms whereby guanosine may exert its neuroprotective effects in vivo. This work provides a basis for further exploration of the purinergic mechanisms underlying the neuroprotective effects of exogenous guanosine. Furthermore, and of potential clinical importance, is that guanosine was effective when it was administered 4 h after the injury—a realistic time frame in which to initiate treatment after spinal cord injury in humans.
We thank Dr. Raelene Kinlough-Rathbone for her helpful suggestions and critical appraisal of the manuscript. Shucui Jiang is recipient of a Chris Beehler Faculty Investigator Award from the Canadian Spinal Research Organization.